| Report Code: 40247 | Published: June 2019 | Pages: 464 | Available format: |
| Therapeutic Area(s): | Oncology | Report Type: Competitive Landscape Reports |
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Marketed Drugs by Route of Administration
1.3.2 Pipeline Drugs by Phase
1.3.3 Pipeline Drugs by Route of Administration
1.4 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 By industry participant
2.2.1.2 By geography
2.2.1.3 By designation
2.2.2 Key Opinion Leaders (KOLs) Validation
2.3 Coverage of Epidemiology Analysis
2.4 Forecast Methodology
2.5 Assumptions for the Study
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1 Disease Overview
4.2 Causes and Risk Factors
4.3 Prognosis
4.4 Signs and Symptoms
4.5 Pathophysiology
4.6 Diagnosis
4.7 Treatment
4.8 Treatment Algorithm for Pancreatic Cancer
4.9 Key Drivers
4.9.1 Rising Incidence of Pancreatic Cancer
4.9.2 Increasing Awareness
4.9.3 Rising R&D Investments
4.9.4 Rising Number of Product Launches
4.10 Key Barriers
4.10.1 Late Observation of Signs and Symptoms at its Early Stage
4.10.2 Patent Expiry of Blockbuster Drugs
4.10.3 High Treatment Cost of Current Treatment
4.11 Opportunities
4.11.1 Aftermath of Current Treatments
4.12 Technology Overview
4.13 Drug Designations
4.14 Unmet Medical Needs
4.14.1 Improvement in Drug Efficacy
4.14.2 Early Diagnosis
4.14.3 Increasing Usage of Available Approved Therapy
4.14.4 Need of Defined Treatment Algorithm
4.14.5 Improvement Required in 3rd Line Settings
Chapter 5. Pancreatic Cancer Epidemiology Forecast for 7MM
5.1 Epidemiology Forecast for 7MM
5.1.1 By Stage
5.1.2 By Sex
5.1.3 By Age Group
5.2 Epidemiology Forecast for the U.S.
5.2.1 By Stage
5.2.2 By Sex
5.2.3 By Age Group
5.3 Epidemiology Forecast for EU5
5.3.1 By Stage
5.3.2 By Sex
5.3.3 By Age Group
5.3.4 By Country
5.3.4.1 Germany
5.3.4.1.1 By stage
5.3.4.1.2 By sex
5.3.4.1.3 By age group
5.3.4.2 France
5.3.4.2.1 By stage
5.3.4.2.2 By sex
5.3.4.2.3 By age group
5.3.4.3 Italy
5.3.4.3.1 By stage
5.3.4.3.2 By sex
5.3.4.3.3 By age group
5.3.4.4 U.K.
5.3.4.4.1 By stage
5.3.4.4.2 By sex
5.3.4.4.3 By age group
5.3.4.5 Spain
5.3.4.5.1 By stage
5.3.4.5.2 By sex
5.3.4.5.3 By age group
5.4 Epidemiology Forecast for Japan
5.4.1 By Stage
5.4.2 By Sex
5.4.3 By Age Group
Chapter 6. Marketed and Pipeline Drugs Outlook
6.1 Marketed Drugs Snapshot
6.1.1 By Route of Administration
6.1.2 By Company
6.2 Pipeline Drugs Snapshot
6.2.1 Pipeline Drugs Snapshot by Phase
6.2.2 Pipeline Drugs Snapshot by Route of Administration
6.2.3 Pipeline Drugs Snapshot by Molecule Type
6.2.4 Pipeline Drugs Snapshot by Company
Chapter 7. Pancreatic Cancer Marketed Drugs Analysis
7.1 Marketed Drugs Profiles
7.1.1 Sutent
7.1.1.1 Product description
7.1.1.2 Dosage
7.1.1.3 Regulatory milestones
7.1.1.4 Clinical trials and results
7.1.1.5 Patents
7.1.1.6 SWOT analysis
7.1.2 Xxxx
7.1.2.1 Product description
7.1.2.2 Dosage
7.1.2.3 Regulatory milestones
7.1.2.4 Clinical trials and results
7.1.2.5 Strategic developments
7.1.2.6 SWOT analysis
7.1.3 Xxxx
7.1.3.1 Product description
7.1.3.2 Dosage
7.1.3.3 Regulatory milestones
7.1.3.4 Clinical trials and results
7.1.3.5 SWOT analysis
7.1.4 Xxxx
7.1.4.1 Product description
7.1.4.2 Dosage
7.1.4.3 Regulatory milestones
7.1.4.4 Clinical trials and results
7.1.4.5 Strategic developments
7.1.4.6 SWOT analysis
7.1.5 Xxxx
7.1.5.1 Product description
7.1.5.2 Dosage
7.1.5.3 Regulatory milestones
7.1.5.4 Clinical trials and results
7.1.5.5 Strategic developments
7.1.5.6 Patents
7.1.5.7 SWOT analysis
7.1.6 Xxxx
7.1.6.1 Product description
7.1.6.2 Dosage
7.1.6.3 Regulatory milestones
7.1.6.4 Clinical trials and results
7.1.6.5 Strategic developments
7.1.6.6 SWOT analysis
7.1.7 Xxxx
7.1.7.1 Product description
7.1.7.2 Dosage
7.1.7.3 Regulatory milestones
7.1.7.4 Clinical trials and results
7.1.7.5 Strategic developments
7.1.7.6 Patents
7.1.7.7 Case study
7.1.7.8 SWOT analysis
7.1.8 Xxxx
7.1.8.1 Product description
7.1.8.2 Dosage
7.1.8.3 Regulatory milestones
7.1.8.4 Clinical trials and results
7.1.8.5 Strategic developments
7.1.8.6 Case study
7.1.8.7 SWOT analysis
7.1.9 Xxxx
7.1.9.1 Product description
7.1.9.2 Dosage
7.1.9.3 SWOT analysis
7.2 Global Pancreatic Cancer Therapeutics Market Size and Share
7.2.1 Market Size
7.2.2 Market Share
7.3 Challenges Faced by Marketed Drug Manufacturers
7.3.1 Increasing Competition
7.3.2 High Cost of Drugs Targeting Pancreatic Cancer
Chapter 8. Pancreatic Cancer Pipeline Drugs Analysis
8.1 Phase III
8.1.1 Masitinib
8.1.1.1 Pre-clinical results
8.1.1.2 Clinical trials
8.1.1.3 Clinical trial results
8.1.1.4 Designations
8.1.1.5 Patents
8.1.2 Xxxx
8.1.2.1 Pre-clinical results
8.1.2.2 Clinical trials
8.1.2.3 Clinical trial results
8.1.2.4 Designations
8.1.3 Xxxx
8.1.3.1 Clinical trials
8.1.3.2 Clinical trial results
8.1.4 Xxxx
8.1.4.1 Pre-clinical trials
8.1.4.2 Clinical trials
8.1.4.3 Clinical trial results
8.1.4.4 Strategic developments
8.1.4.5 Designations
8.1.4.6 Financing
8.1.4.7 Patents
8.1.5 Xxxx
8.1.5.1 Clinical trials
8.1.5.2 Clinical trial results
8.1.5.3 Designations
8.1.6 Xxxx
8.1.6.1 Pre-clinical results
8.1.6.2 Clinical trials
8.1.6.3 Clinical trial results
8.1.6.4 Strategic developments
8.1.6.5 Designations
8.1.7 Xxxx
8.1.7.1 Clinical trials
8.1.7.2 Clinical trial results
8.1.7.3 Strategic developments
8.1.7.4 Designations
8.2 Phase II
8.2.1 Pamrevlumab
8.2.1.1 Clinical trials
8.2.1.2 Clinical trial results
8.2.1.3 Designations
8.2.2 Xxxx
8.2.2.1 Pre-clinical results
8.2.2.2 Clinical trials
8.2.2.3 Clinical trial results
8.2.2.4 Designations
8.2.3 Xxxx
8.2.3.1 Pre-clinical studies
8.2.3.2 Clinical trials
8.2.3.3 Clinical trial results
8.2.3.4 Strategic developments
8.2.4 Xxxx
8.2.4.1 Pre-clinical studies
8.2.4.2 Clinical trials
8.2.4.3 Clinical trial results
8.2.4.4 Strategic developments
8.2.4.5 Designations
8.2.5 Xxxx
8.2.5.1 Pre-clinical studies
8.2.5.2 Clinical trials
8.2.5.3 Clinical trial results
8.2.5.4 Designations
8.2.6 Xxxx
8.2.6.1 Pre-clinical results
8.2.6.2 Clinical trials
8.2.6.3 Clinical trial results
8.2.6.4 Technology
8.2.6.5 Designations
8.2.6.6 Patents
8.2.7 Xxxx
8.2.7.1 Clinical trials
8.2.7.2 Clinical trial results
8.2.8 Xxxx
8.2.8.1 Clinical trials
8.2.8.2 Clinical trial results
8.2.8.3 Designations
8.2.8.4 Strategic developments
8.2.8.5 Patents
8.2.9 Xxxx
8.2.9.1 Pre-clinical studies
8.2.9.2 Clinical trials
8.2.9.3 Clinical trial results
8.2.9.4 Strategic developments
8.2.10 Xxxx
8.2.10.1 Clinical trials
8.2.10.2 Clinical trial results
8.2.10.3 Designations
8.2.10.4 Technology
8.2.11 Xxxx
8.2.11.1 Clinical trials
8.2.12 Xxxx
8.2.12.1 Clinical trials
8.2.12.2 Clinical trial results
8.2.12.3 Strategic developments
8.2.13 Xxxx
8.2.13.1 Pre-clinical studies
8.2.13.2 Clinical trials
8.2.14 Xxxx
8.2.14.1 Clinical trials
8.2.14.2 Strategic developments
8.2.14.3 Technology
8.2.15 Xxxx
8.2.15.1 Clinical trials
8.2.15.2 Designations
8.2.15.3 Patents
8.2.16 Xxxx
8.2.16.1 Clinical trials
8.2.16.2 Clinical trial results
8.2.16.3 Technology
8.2.17 Xxxx
8.2.17.1 Clinical trials
8.2.17.2 Clinical trial results
8.2.18 Xxxx
8.2.18.1 Pre-clinical studies
8.2.18.2 Clinical trials
8.2.18.3 Clinical trial results
8.2.19 Xxxx
8.2.19.1 Pre-clinical studies
8.2.19.2 Clinical trials
8.2.19.3 Clinical trial results
8.2.19.4 Strategic developments
8.2.19.5 Designations
8.2.20 Xxxx
8.2.20.1 Clinical trials
8.2.20.2 Strategic developments
8.2.20.3 Financing
8.2.21 Xxxx
8.2.21.1 Clinical trials
8.2.21.2 Strategic developments
8.2.22 List of Other Phase II Drugs
8.3 Phase I
8.3.1 Resminostat
8.3.1.1 Pre-clinical results
8.3.1.2 Clinical trials
8.3.1.3 Clinical trial results
8.3.1.4 Strategic developments
8.3.2 Xxxx
8.3.2.1 Clinical trials
8.3.2.2 Clinical trial results
8.3.2.3 Strategic developments
8.3.2.4 Patents
8.3.3 Xxxx
8.3.3.1 Clinical trials
8.3.3.2 Clinical trial results
8.3.3.3 Patents
8.3.4 Xxxx
8.3.4.1 Pre-clinical studies
8.3.4.2 Clinical trials
8.3.4.3 Clinical trial results
8.3.4.4 Strategic developments
8.3.4.5 Designations
8.3.4.6 Patents
8.3.5 Xxxx
8.3.5.1 Pre-clinical studies
8.3.5.2 Clinical trials
8.3.5.3 Clinical trial results
8.3.5.4 Patents
8.3.6 Xxxx
8.3.6.1 Pre-clinical results
8.3.6.2 Clinical trials
8.3.6.3 Patent
8.3.7 Xxxx
8.3.7.1 Pre-clinical results
8.3.7.2 Clinical trials
8.3.7.3 Patent
8.3.8 Xxxx
8.3.8.1 Pre-clinical results
8.3.8.2 Clinical trials
8.3.8.3 Clinical trial results
8.3.8.4 Designations
8.3.8.5 Technology
8.3.9 Xxxx
8.3.9.1 Pre-clinical results
8.3.9.2 Clinical trials
8.3.9.3 Clinical trial results
8.3.9.4 Strategic developments
8.3.9.5 Patent
8.3.10 Xxxx
8.3.10.1 Clinical trials
8.3.10.2 Clinical trial results
8.3.10.3 Financing
8.3.10.4 Patent
8.3.11 Xxxx
8.3.11.1 Pre-clinical studies
8.3.11.2 Clinical trials
8.3.11.3 Clinical trial results
8.3.11.4 Strategic developments
8.3.11.5 Grants
8.3.12 Xxxx
8.3.12.1 Clinical trials
8.3.12.2 Strategic developments
8.3.12.3 Patents
8.3.13 Xxxx
8.3.13.1 Pre-clinical studies
8.3.13.2 Clinical trials
8.3.13.3 Strategic developments
8.3.13.4 Designations
8.3.13.5 Patents
8.3.14 Xxxx
8.3.14.1 Clinical trials
8.3.15 Xxxx
8.3.15.1 Pre-clinical studies
8.3.15.2 Clinical trials
8.3.15.3 Clinical trial results
8.3.15.4 Strategic developments
8.3.15.5 Patents
8.3.16 List of Other Phase I Drugs
8.4 Pre-Clinical
8.4.1 OMTX705
8.4.1.1 Pre-clinical studies
8.4.2 Xxxx
8.4.2.1 Pre-clinical studies
8.4.2.2 Strategic developments
8.4.2.3 Technology
8.4.3 Xxxx
8.4.3.1 Pre-clinical studies
8.4.3.2 Strategic developments
8.4.3.3 Technology
8.4.4 Xxxx
8.4.4.1 Pre-clinical studies and results
8.4.5 Xxxx
8.4.6 Xxxx
8.4.6.1 Pre-clinical studies
8.4.6.2 Technology
8.4.6.3 Strategic developments
8.4.7 Xxxx
8.4.7.1 Technology
8.4.8 Xxxx
8.4.8.1 Technology
8.4.8.2 Patents
8.4.9 Xxxx
8.4.9.1 Pre-clinical studies
8.4.10 Xxxx
8.4.10.1 Technology
8.4.11 Xxxx
8.4.11.1 Designations
8.4.12 Xxxx
8.4.12.1 Pre-clinical studies
8.4.12.2 Strategic developments
8.4.13 Xxxx
8.4.13.1 Pre-clinical studies
8.4.13.2 Technology
8.4.13.3 Strategic developments
8.4.14 Xxxx
8.4.14.1 Pre-clinical studies
8.4.14.2 Technology
8.4.14.3 Designations
8.4.15 Xxxx
8.4.16 List of Other Pre-Clinical Drugs
8.5 Discovery
8.5.1 NBE-003
8.5.1.1 Strategic developments
8.5.1.2 Technology
8.5.2 Xxxx
8.5.3 Xxxx
8.5.4 Xxxx
8.5.5 Xxxx
8.5.5.1 Technology
Chapter 9. Clinical Trials Review
9.1 Clinical Trials by Geography
9.2 Clinical Trials by Trial Status
Chapter 10. Regulatory Framework for Drug Approval
10.1 U.S.
10.2 Europe
10.2.1 Centralized Procedure
10.2.2 Mutual Recognition Procedure
10.2.3 Decentralized Procedure
10.2.4 Nationalized Procedures
10.3 Japan
Chapter 11. Competitive Landscape
11.1 Summary of Strategic Development Activities
11.2 Comparative Analysis of Marketed and Phase III Drugs
11.3 Attribute Analysis
11.3.1 Safety
11.3.2 Efficacy
11.3.3 USP
11.4 Expected Launch Time of Phase III Clinical Stage Products
11.5 Key Winning Strategies
11.5.1 Technological Advancements
11.5.2 Collaborations
11.5.3 Development through Subsidiaries
11.5.4 Acquisition of Additional Pipeline Products
11.6 Pharma Proff’s View
Chapter 12. Company Profiles
12.1 Pfizer Inc.
12.1.1 Business Overview
12.1.2 Product and Service Offerings
12.1.2.1 Marketed products
12.2 Xxxx
12.2.1 Business Overview
12.2.2 Product and Service Offerings
12.2.2.1 Marketed products
12.3 Xxxx
12.3.1 Business Overview
12.3.2 Product and Service Offerings
12.3.2.1 Marketed products
12.4 Xxxx
12.4.1 Business Overview
12.4.2 Product and Service Offerings
12.4.2.1 Marketed Products
12.5 Xxxx.
12.5.2 Product and Service Offerings
12.5.1 Business Overview
12.5.2.1 Marketed Products
12.6 Xxxx
12.6.1 Business Overview
12.6.2 Product and Service Offerings
12.6.2.1 Marketed Products
12.7 Xxxx
12.7.1 Business Overview
12.7.2 Product and Service Offerings
12.7.2.1 Marketed products
12.8 Xxxx
12.8.1 Business Overview
12.8.2 Product and Service Offerings
12.8.2.1 Pipeline Products
12.9 Xxxx.
12.9.1 Business Overview
12.9.2 Product and Service Offerings
12.9.2.1 Marketed products
12.9.2.2 Pipeline products
12.10 Xxxx
12.10.1 Business Overview
12.10.2 Product and Service Offerings
12.10.2.1 Pipeline products
12.11 Xxxx.
12.11.1 Business Overview
12.11.2 Product and Service Offerings
12.11.2.1 Marketed products
12.11.2.2 Pipeline products
12.12 Xxxx
12.12.1 Business Overview
12.12.2 Product and Service Offerings
12.12.2.1 Marketed products
12.12.2.2 Pipeline products
12.13 Xxxx.
12.13.1 Business Overview
12.13.2 Product and Service Offerings
12.13.2.1 Marketed products
12.13.2.2 Pipeline products
12.14 Xxxx
12.14.1 Business Overview
12.14.2 Product and Service Offerings
12.14.2.1 Pipeline products
12.15 Xxxx.
12.15.1 Business Overview
12.15.2 Product and Service Offerings
12.15.2.1 Pipeline products
12.16 Xxxx
12.16.1 Business Overview
12.16.2 Product and Service Offerings
12.16.2.1 Pipeline products
12.17 Xxxx
12.17.1 Business Overview
12.17.2 Product and Service Offerings
12.17.2.1 Marketed products
12.17.2.2 Pipeline products
12.18 Xxxx
12.18.1 Business Overview
12.18.2 Product and Service Offerings
12.19 Xxxx
12.19.1 Business Overview
12.19.2 Product and Service Offerings
12.19.2.1 Marketed products
12.19.2.2 Pipeline products
12.20 Xxxx
12.20.1 Business Overview
12.20.2 Product and Service Offerings
12.20.2.1 Marketed products
12.20.2.2 Pipeline products
12.21 Xxxx
12.21.1 Business Overview
12.21.2 Product and Service Offerings
12.21.2.1 Marketed products
12.21.2.2 Pipeline products
12.22 Xxxx
12.22.1 Business Overview
12.22.2 Product and Service Offerings
12.22.2.1 Pipeline Products
12.23 Xxxx.
12.23.1 Business Overview
12.23.2 Product and Service Offerings
12.23.2.1 Marketed products
12.23.2.2 Pipeline products
12.24 Xxxx
12.24.1 Business Overview
12.24.2 Product and Service Offerings
12.24.2.1 Pipeline Products
12.25 Xxxx
12.25.1 Business Overview
12.25.2 Product and Service Offerings
12.25.2.1 Marketed products
12.25.2.2 Pipeline products
12.26 Xxxx
12.26.1 Business Overview
12.26.2 Product and Service Offerings
12.26.2.1 Pipeline Products
12.27 Xxxx.
12.27.1 Business Overview
12.27.2 Product and Service Offerings
Chapter 13. Appendix
13.1 Recently Organized/Held Seminars and Conferences
13.2 Upcoming Conferences
13.3 Sources and References
13.4 Abbreviations
13.5 Related Reports
List of Tables
TABLE 1 DESIGNATIONS FOR SOME PANCREATIC CANCER DRUGS
TABLE 2 PANCREATIC CANCER EPIDEMIOLOGY IN 7MM (2016-2021)
TABLE 3 PANCREATIC CANCER EPIDEMIOLOGY IN 7MM (2022-2028)
TABLE 4 PANCREATIC CANCER INCIDENT CASES IN 7MM, BY STAGE (2016-2021)
TABLE 5 PANCREATIC CANCER INCIDENT CASES IN 7MM, BY STAGE (2022-2028)
TABLE 6 PANCREATIC CANCER INCIDENT CASES IN 7MM, BY SEX (2016-2021)
TABLE 7 PANCREATIC CANCER INCIDENT CASES IN 7MM, BY SEX (2022-2028)
TABLE 8 PANCREATIC CANCER INCIDENT CASES IN 7MM, BY AGE GROUP (2016-2021)
TABLE 9 PANCREATIC CANCER INCIDENT CASES IN 7MM, BY AGE GROUP (2022-2028)
TABLE 10 PANCREATIC CANCER EPIDEMIOLOGY IN THE U.S. (2016-2021)
TABLE 11 PANCREATIC CANCER EPIDEMIOLOGY IN THE U.S. (2022-2028)
TABLE 12 PANCREATIC CANCER INCIDENT CASES IN THE U.S., BY STAGE (2016-2021)
TABLE 13 PANCREATIC CANCER INCIDENT CASES IN THE U.S., BY STAGE (2022-2028)
TABLE 14 PANCREATIC CANCER INCIDENT CASES IN THE U.S., BY SEX (2016-2021)
TABLE 15 PANCREATIC CANCER INCIDENT CASES IN THE U.S., BY SEX (2022-2028)
TABLE 16 PANCREATIC CANCER INCIDENT CASES IN THE U.S., BY AGE GROUP (2016-2021)
TABLE 17 PANCREATIC CANCER INCIDENT CASES IN THE U.S., BY AGE GROUP (2022-2028)
TABLE 18 PANCREATIC CANCER EPIDEMIOLOGY IN EU5 (2016-2021)
TABLE 19 PANCREATIC CANCER EPIDEMIOLOGY IN EU5 (2022-2028)
TABLE 20 PANCREATIC CANCER INCIDENT CASES IN EU5, BY STAGE (2016-2021)
TABLE 21 PANCREATIC CANCER INCIDENT CASES IN EU5, BY STAGE (2022-2028)
TABLE 22 PANCREATIC CANCER INCIDENT CASES IN EU5, BY SEX (2016-2021)
TABLE 23 PANCREATIC CANCER INCIDENT CASES IN EU5, BY SEX (2022-2028)
TABLE 24 PANCREATIC CANCER INCIDENT CASES IN EU5, BY AGE GROUP (2016-2021)
TABLE 25 PANCREATIC CANCER INCIDENT CASES IN EU5, BY AGE GROUP (2022-2028)
TABLE 26 PANCREATIC CANCER EPIDEMIOLOGY IN GERMANY (2016-2021)
TABLE 27 PANCREATIC CANCER EPIDEMIOLOGY IN GERMANY (2022-2028)
TABLE 28 PANCREATIC CANCER INCIDENT CASES IN GERMANY, BY STAGE (2016-2021)
TABLE 29 PANCREATIC CANCER INCIDENT CASES IN GERMANY, BY STAGE (2022-2028)
TABLE 30 PANCREATIC CANCER INCIDENT CASES IN GERMANY, BY SEX (2016-2021)
TABLE 31 PANCREATIC CANCER INCIDENT CASES IN GERMANY, BY SEX (2022-2028)
TABLE 32 PANCREATIC CANCER INCIDENT CASES IN GERMANY, BY AGE GROUP (2016-2021)
TABLE 33 PANCREATIC CANCER INCIDENT CASES IN GERMANY, BY AGE GROUP (2022-2028)
TABLE 34 PANCREATIC CANCER EPIDEMIOLOGY IN FRANCE (2016-2021)
TABLE 35 PANCREATIC CANCER EPIDEMIOLOGY IN FRANCE (2022-2028)
TABLE 36 PANCREATIC CANCER INCIDENT CASES IN FRANCE, BY STAGE (2016-2021)
TABLE 37 PANCREATIC CANCER INCIDENT CASES IN FRANCE, BY STAGE (2022-2028)
TABLE 38 PANCREATIC CANCER INCIDENT CASES IN FRANCE, BY SEX (2016-2021)
TABLE 39 PANCREATIC CANCER INCIDENT CASES IN FRANCE, BY SEX (2022-2028)
TABLE 40 PANCREATIC CANCER INCIDENT CASES IN FRANCE, BY AGE GROUP (2016-2021)
TABLE 41 PANCREATIC CANCER INCIDENT CASES IN FRANCE, BY AGE GROUP (2022-2028)
TABLE 42 PANCREATIC CANCER EPIDEMIOLOGY IN ITALY (2016-2021)
TABLE 43 PANCREATIC CANCER EPIDEMIOLOGY IN ITALY (2022-2028)
TABLE 44 PANCREATIC CANCER INCIDENT CASES IN ITALY, BY STAGE (2016-2021)
TABLE 45 PANCREATIC CANCER INCIDENT CASES IN ITALY, BY STAGE (2022-2028)
TABLE 46 PANCREATIC CANCER INCIDENT CASES IN ITALY, BY SEX (2016-2021)
TABLE 47 PANCREATIC CANCER INCIDENT CASES IN ITALY, BY SEX (2022-2028)
TABLE 48 PANCREATIC CANCER INCIDENT CASES IN ITALY, BY AGE GROUP (2016-2021)
TABLE 49 PANCREATIC CANCER INCIDENT CASES IN ITALY, BY AGE GROUP (2022-2028)
TABLE 52 PANCREATIC CANCER INCIDENT CASES IN THE U.K., BY STAGE (2016-2021)
TABLE 53 PANCREATIC CANCER INCIDENT CASES IN THE U.K., BY STAGE (2022-2028)
TABLE 54 PANCREATIC CANCER INCIDENT CASES IN THE U.K., BY SEX (2016-2021)
TABLE 55 PANCREATIC CANCER INCIDENT CASES IN THE U.K., BY SEX (2022-2028)
TABLE 56 PANCREATIC CANCER INCIDENT CASES IN THE U.K., BY AGE GROUP (2016-2021)
TABLE 57 PANCREATIC CANCER INCIDENT CASES IN THE U.K., BY AGE GROUP (2022-2028)
TABLE 58 PANCREATIC CANCER EPIDEMIOLOGY IN SPAIN (2016-2021)
TABLE 59 PANCREATIC CANCER EPIDEMIOLOGY IN SPAIN (2022-2028)
TABLE 60 PANCREATIC CANCER INCIDENT CASES IN SPAIN, BY STAGE (2016-2021)
TABLE 61 PANCREATIC CANCER INCIDENT CASES IN SPAIN, BY STAGE (2022-2028)
TABLE 62 PANCREATIC CANCER INCIDENT CASES IN SPAIN, BY SEX (2016-2021)
TABLE 63 PANCREATIC CANCER INCIDENT CASES IN SPAIN, BY SEX (2022-2028)
TABLE 64 PANCREATIC CANCER INCIDENT CASES IN SPAIN, BY AGE GROUP (2016-2021)
TABLE 65 PANCREATIC CANCER INCIDENT CASES IN SPAIN, BY AGE GROUP (2022-2028)
TABLE 66 PANCREATIC CANCER EPIDEMIOLOGY IN JAPAN (2016-2021)
TABLE 67 PANCREATIC CANCER EPIDEMIOLOGY IN JAPAN (2022-2028)
TABLE 68 PANCREATIC CANCER INCIDENT CASES IN JAPAN, BY STAGE (2016-2021)
TABLE 69 PANCREATIC CANCER INCIDENT CASES IN JAPAN, BY STAGE (2022-2028)
TABLE 70 PANCREATIC CANCER INCIDENT CASES IN JAPAN, BY SEX (2016-2021)
TABLE 71 PANCREATIC CANCER INCIDENT CASES IN JAPAN, BY SEX (2022-2028)
TABLE 72 PANCREATIC CANCER INCIDENT CASES IN JAPAN, BY AGE GROUP (2016-2021)
TABLE 73 PANCREATIC CANCER INCIDENT CASES IN JAPAN, BY AGE GROUP (2022-2028)
TABLE 74 DESCRIPTION OF SUTENT
TABLE 75 DESCRIPTION OF XXXX
TABLE 76 DESCRIPTION OF XXXX
TABLE 77 DESCRIPTION OF XXXX
TABLE 78 DESCRIPTION OF XXXX
TABLE 79 PATENTS OF XXXX
TABLE 80 DESCRIPTION OF XXXX
TABLE 81 RESULTS OF XXXX
TABLE 82 DESCRIPTION OF XXXX
TABLE 83 SUMMARY OF DISEASE CHARACTERISTICS IN THE STUDY POPULATION
TABLE 84 DESCRIPTION OF XXXX
TABLE 85 DESCRIPTION OF XXXX
TABLE 86 GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, $M (2018-2023)
TABLE 87 GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, $M (2024-2028)
TABLE 88 DESCRIPTION OF MASITINIB
TABLE 89 CLINICAL TRIALS OF MASITINIB
TABLE 90 DESCRIPTION OF XXXX
TABLE 91 CLINICAL TRIALS OF XXXX
TABLE 92 DESCRIPTION OF XXXX
TABLE 93 CLINICAL TRIALS OF XXXX
TABLE 94 DESCRIPTION OF XXXX
TABLE 95 CLINICAL TRIALS OF XXXX
TABLE 96 DESCRIPTION OF XXXX
TABLE 97 CLINICAL TRIALS OF XXXX
TABLE 98 DESCRIPTION OF XXXX
TABLE 99 CLINICAL TRIALS OF XXXX
TABLE 100 DESCRIPTION OF XXXX
TABLE 101 CLINICAL TRIALS OF XXXX
TABLE 102 DESCRIPTION OF PAMREVLUMAB
TABLE 103 CLINICAL TRIALS OF PAMREVLUMAB
TABLE 104 DESCRIPTION OF XXXX
TABLE 105 CLINICAL TRIALS OF XXXX
TABLE 106 DESCRIPTION OF XXXX
TABLE 107 CLINICAL TRIALS OF XXXX
TABLE 108 DESCRIPTION OF XXXX
TABLE 109 CLINICAL TRIALS OF XXXX
TABLE 110 DESCRIPTION OF XXXX
TABLE 111 CLINICAL TRIALS OF XXXX
TABLE 112 DESCRIPTION OF XXXX
TABLE 113 CLINICAL TRIALS OF XXXX
TABLE 114 PATENTS OF XXXX
TABLE 115 DESCRIPTION OF XXXX
TABLE 116 CLINICAL TRIALS OF XXXX
TABLE 117 DESCRIPTION OF XXXX
TABLE 118 CLINICAL TRIALS OF XXXX
TABLE 119 PATENTS OF XXXX
TABLE 120 DESCRIPTION OF XXXX
TABLE 121 CLINICAL TRIALS OF XXXX
TABLE 122 DESCRIPTION OF XXXX
TABLE 123 CLINICAL TRIALS OF XXXX
TABLE 124 DESCRIPTION OF XXXX
TABLE 125 CLINICAL TRIALS OF XXXX
TABLE 126 DESCRIPTION OF XXXX
TABLE 127 CLINICAL TRIALS OF XXXX
TABLE 128 DESCRIPTION OF XXXX
TABLE 129 CLINICAL TRIALS OF XXXX
TABLE 130 DESCRIPTION OF XXXX
TABLE 131 CLINICAL TRIALS OF XXXX
TABLE 132 DESCRIPTION OF XXXX
TABLE 133 CLINICAL TRIALS OF XXXX
TABLE 134 PATENTS OF XXXX
TABLE 135 DESCRIPTION OF XXXX
TABLE 136 CLINICAL TRIALS OF XXXX
TABLE 137 DESCRIPTION OF XXXX
TABLE 138 CLINICAL TRIALS OF XXXX
TABLE 139 DESCRIPTION OF XXXX
TABLE 140 CLINICAL TRIALS OF XXXX
TABLE 141 DESCRIPTION OF XXXX
TABLE 142 CLINICAL TRIALS OF XXXX
TABLE 143 DESCRIPTION OF XXXX
TABLE 144 CLINICAL TRIALS OF XXXX
TABLE 145 DESCRIPTION OF XXXX
TABLE 146 CLINICAL TRIALS OF XXXX
TABLE 147 OTHER PHASE II DRUGS
TABLE 148 DESCRIPTION OF RESMINOSTAT
TABLE 149 CLINICAL TRIALS OF RESMINOSTAT
TABLE 150 DESCRIPTION OF XXXX
TABLE 151 CLINICAL TRIALS OF XXXX
TABLE 152 PATENTS OF XXXX
TABLE 153 DESCRIPTION OF XXXX
TABLE 154 CLINICAL TRIALS OF XXXX
TABLE 155 PATENTS OF XXXX
TABLE 156 DESCRIPTION OF XXXX
TABLE 157 CLINICAL TRIALS OF XXXX
TABLE 158 DESCRIPTION OF XXXX
TABLE 159 CLINICAL TRIALS OF XXXX
TABLE 160 PATENTS OF XXXX
TABLE 161 DESCRIPTION OF XXXX
TABLE 162 CLINICAL TRIALS OF XXXX
TABLE 163 PATENTS OF XXXX
TABLE 164 DESCRIPTION OF XXXX
TABLE 165 CLINICAL TRIALS OF XXXX
TABLE 166 PATENTS OF XXXX
TABLE 167 DESCRIPTION OF XXXX
TABLE 168 CLINICAL TRIALS OF XXXX
TABLE 169 DESCRIPTION OF XXXX
TABLE 170 CLINICAL TRIALS OF XXXX
TABLE 171 PATENTS OF XXXX
TABLE 172 DESCRIPTION OF XXXX
TABLE 173 CLINICAL TRIALS OF XXXX
TABLE 174 PATENTS OF XXXX
TABLE 175 DESCRIPTION OF XXXX
TABLE 176 CLINICAL TRIALS OF XXXX
TABLE 177 DESCRIPTION OF XXXX
TABLE 178 CLINICAL TRIALS OF XXXX
TABLE 179 PATENTS OF XXXX
TABLE 180 DESCRIPTION OF XXXX
TABLE 181 CLINICAL TRIALS OF XXXX
TABLE 182 PATENTS OF XXXX
TABLE 183 DESCRIPTION OF XXXX
TABLE 184 CLINICAL TRIALS OF XXXX
TABLE 185 DESCRIPTION OF XXXX
TABLE 186 CLINICAL TRIALS OF XXXX
TABLE 187 PATENT OF XXXX
TABLE 188 OTHER PHASE I DRUGS
TABLE 189 DESCRIPTION OF OMTX705
TABLE 190 DESCRIPTION OF XXXX
TABLE 191 DESCRIPTION OF XXXX
TABLE 192 DESCRIPTION OF XXXX
TABLE 193 DESCRIPTION OF XXXX
TABLE 194 DESCRIPTION OF XXXX
TABLE 195 DESCRIPTION OF XXXX
TABLE 196 DESCRIPTION OF XXXX
TABLE 197 DESCRIPTION OF XXXX
TABLE 198 DESCRIPTION OF XXXX
TABLE 199 DESCRIPTION OF XXXX
TABLE 200 DESCRIPTION OF XXXX
TABLE 201 DESCRIPTION OF XXXX
TABLE 202 DESCRIPTION OF XXXX
TABLE 203 DESCRIPTION OF XXXX
TABLE 204 OTHER PRE-CLINICAL DRUGS
TABLE 205 DESCRIPTION OF NBE-003
TABLE 206 DESCRIPTION OF XXXX
TABLE 207 DESCRIPTION OF XXXX
TABLE 208 DESCRIPTION OF XXXX
TABLE 209 DESCRIPTION OF XXXX
TABLE 210 COLLABORATIONS AND LICENSING AGREEMENTS
TABLE 211 MERGERS AND ACQUISITIONS
TABLE 212 OTHER DEVELOPMENTS
TABLE 213 MARKETED DRUGS COMPARISON BASED ON EFFICACY
TABLE 214 COMPARISON OF PHASE III DRUGS
TABLE 215 ATTRIBUTE ANALYSIS
TABLE 216 EXPECTED LAUNCH TIME OF PHASE III CLINICAL STAGE PRODUCTS
TABLE 217 PFIZER INC. – AT A GLANCE
TABLE 218 XXXX – AT A GLANCE
TABLE 219 MARKETED PRODUCTS
TABLE 220 XXXX – AT A GLANCE
TABLE 221 MARKETED PRODUCTS
TABLE 222 XXXX – AT A GLANCE
TABLE 223 XXXX– AT A GLANCE
TABLE 224 MARKETED PRODUCTS
TABLE 225 XXXX – AT A GLANCE
TABLE 226 XXXX – AT A GLANCE
TABLE 227 MARKETED PRODUCTS
TABLE 228 XXXX – AT A GLANCE
TABLE 229 PIPELINE PRODUCTS
TABLE 230 XXXX – AT A GLANCE
TABLE 231 MARKETED PRODUCTS
TABLE 232 PIPELINE PRODUCTS
TABLE 233 XXXX – AT A GLANCE
TABLE 234 PIPELINE PRODUCTS
TABLE 235 XXXX – AT A GLANCE
TABLE 236 PIPELINE PRODUCTS
TABLE 237 XXXX – AT A GLANCE
TABLE 238 PIPELINE PRODUCTS
TABLE 239 XXXX – AT A GLANCE
TABLE 240 PIPELINE PRODUCTS
TABLE 241 XXXX – AT A GLANCE
TABLE 242 PIPELINE PRODUCTS
TABLE 243 XXXX – AT A GLANCE
TABLE 244 PIPELINE PRODUCTS
TABLE 245 XXXX – AT A GLANCE
TABLE 246 PIPELINE PRODUCTS
TABLE 247 XXXX – AT A GLANCE
TABLE 248 PIPELINE PRODUCTS
TABLE 249 XXXX – AT A GLANCE
TABLE 250 XXXX – AT A GLANCE
TABLE 251 MARKETED PRODUCTS
TABLE 252 XXXX – AT A GLANCE
TABLE 253 MARKETED PRODUCTS
TABLE 254 PIPELINE PRODUCTS
TABLE 255 XXXX – AT A GLANCE
TABLE 256 MARKETED PRODUCTS
TABLE 257 PIPELINE PRODUCTS
TABLE 258 XXXX – AT A GLANCE
TABLE 259 PIPELINE PRODUCTS
TABLE 260 XXXX– AT A GLANCE
TABLE 261 PIPELINE PRODUCTS
TABLE 262 XXXX – AT A GLANCE
TABLE 263 PIPELINE PRODUCTS
TABLE 264 XXXX – AT A GLANCE
TABLE 265 MARKETED PRODUCT
TABLE 266 PIPELINE PRODUCTS
TABLE 267 XXXX – AT A GLANCE
TABLE 268 PIPELINE PRODUCTS
TABLE 269 XXXX – AT A GLANCE
TABLE 270 RECENTLY ORGANIZED SEMINARS AND CONFERENCES
TABLE 271 UPCOMING SEMINARS AND CONFERENCES
TABLE 272 SOURCES AND REFERENCES
TABLE 273 ABBREVIATIONS
List of Figures
FIG 1 RESEARCH METHODOLOGY
FIG 2 BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT
FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY GEOGRAPHY
FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY DESIGNATION
FIG 5 PANCREATIC CANCER EPIDIEMOLOGY SUMMARY
FIG 6 CORE SIGNALING PATHWAYS IN PANCREATIC CANCER
FIG 7 DIAGNOSTIC ALGORITHM FOR SUSPECTED PANCREATIC CANCER
FIG 8 TREATMENT ALGORITHM FOR PANCREATIC CANCER
FIG 9 PANCREATIC CANCER – UNMET NEEDS
FIG 10 TOTAL NUMBER OF INCIDENT CASES IN 7MM (2016 & 2028)
FIG 11 PANCREATIC CANCER INCIDENT CASES IN 7MM (2016-2028)
FIG 12 PANCREATIC CANCER INCIDENT CASES IN 7MM, BY STAGE (2016-2028)
FIG 13 PANCREATIC CANCER INCIDENT CASES IN 7MM, BY SEX (2016-2028)
FIG 14 PANCREATIC CANCER INCIDENT CASES IN 7MM, BY AGE GROUP (2016-2028)
FIG 15 PANCREATIC CANCER EPIDEMIOLOGY IN THE U.S. (2016-2028)
FIG 16 PANCREATIC CANCER INCIDENT CASES IN THE U.S., BY STAGE (2016-2028)
FIG 17 PANCREATIC CANCER INCIDENT CASES IN THE U.S., BY SEX (2016-2028)
FIG 18 PANCREATIC CANCER INCIDENT CASES IN THE U.S., BY AGE GROUP (2016-2028)
FIG 19 PANCREATIC CANCER EPIDEMIOLOGY IN EU5 (2016-2028)
FIG 20 PANCREATIC CANCER INCIDENT CASES IN EU5, BY STAGE (2016-2028)
FIG 21 PANCREATIC CANCER INCIDENT CASES IN EU5, BY SEX (2016-2028)
FIG 22 PANCREATIC CANCER INCIDENT CASES IN EU5, BY AGE GROUP (2016-2028)
FIG 23 PANCREATIC CANCER EPIDEMIOLOGY IN GERMANY (2016-2028)
FIG 24 PANCREATIC CANCER INCIDENT CASES IN GERMANY, BY STAGE (2016-2028)
FIG 25 PANCREATIC CANCER INCIDENT CASES IN GERMANY, BY SEX (2016-2028)
FIG 26 PANCREATIC CANCER INCIDENT CASES IN GERMANY, BY AGE GROUP (2016-2028)
FIG 27 PANCREATIC CANCER EPIDEMIOLOGY IN FRANCE (2016-2028)
FIG 28 PANCREATIC CANCER INCIDENT CASES IN FRANCE, BY STAGE (2016-2028)
FIG 29 PANCREATIC CANCER INCIDENT CASES IN FRANCE, BY SEX (2016-2028)
FIG 30 PANCREATIC CANCER INCIDENT CASES IN FRANCE, BY AGE GROUP (2016-2028)
FIG 31 PANCREATIC CANCER EPIDEMIOLOGY IN ITALY (2016-2028)
FIG 32 PANCREATIC CANCER INCIDENT CASES IN ITALY, BY STAGE (2016-2028)
FIG 33 PANCREATIC CANCER INCIDENT CASES IN ITALY, BY SEX (2016-2028)
FIG 34 PANCREATIC CANCER INCIDENT CASES IN ITALY, BY AGE GROUP (2016-2028)
FIG 35 PANCREATIC CANCER EPIDEMIOLOGY IN THE U.K. (2016-2028)
FIG 36 PANCREATIC CANCER INCIDENT CASES IN THE U.K., BY STAGE (2016-2028)
FIG 37 PANCREATIC CANCER INCIDENT CASES IN THE U.K., BY SEX (2016-2028)
FIG 38 PANCREATIC CANCER INCIDENT CASES IN THE U.K., BY AGE GROUP (2016-2028)
FIG 39 PANCREATIC CANCER EPIDEMIOLOGY IN SPAIN (2016-2028)
FIG 40 PANCREATIC CANCER INCIDENT CASES IN SPAIN, BY STAGE (2016-2028)
FIG 41 PANCREATIC CANCER INCIDENT CASES IN SPAIN, BY SEX (2016-2028)
FIG 42 PANCREATIC CANCER INCIDENT CASES IN SPAIN, BY AGE GROUP (2016-2028)
FIG 43 PANCREATIC CANCER EPIDEMIOLOGY IN JAPAN (2016-2028)
FIG 44 PANCREATIC CANCER INCIDENT CASES IN JAPAN, BY STAGE (2016-2028)
FIG 45 PANCREATIC CANCER INCIDENT CASES IN JAPAN, BY SEX (2016-2028)
FIG 46 PANCREATIC CANCER INCIDENT CASES IN JAPAN, BY AGE GROUP (2016-2028)
FIG 47 PANCREATIC CANCER MARKETED DRUGS SNAPSHOT, BY ROUTE OF ADMINISTRATION (2019)
FIG 48 KEY PLAYERS AND NUMBER OF THEIR MARKETED DRUG CANDIDATES
FIG 49 PANCREATIC CANCER PIPELINE DRUGS SNAPSHOT, BY PHASE (2019)
FIG 50 PANCREATIC CANCER PIPELINE DRUGS SNAPSHOT, BY ROUTE OF ADMINISTRATION (2019)
FIG 51 PANCREATIC CANCER PIPELINE DRUGS SNAPSHOT, BY MOLECULE TYPE (2019)
FIG 52 COMPANY BENCHMARKING BASED ON DRUG CANDIDATES
FIG 53 GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, $M (2018 & 2028)
FIG 54 MARKET SHARE OF PANCREATIC CANCER MARKETED DRUGS (2018)
FIG 55 BREAKDOWN OF CLINICAL TRIALS, BY GEOGRAPHY
FIG 56 BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS
FIG 57 DRUG DISCOVERY AND APPROVAL PROCESS (PRE-CLINICAL AND CLINICAL TRIALS STAGES)
FIG 58 DRUG APPROVAL PROCESS (NDA REVIEW AND POST-MARKETING STAGES)
FIG 59 NEW DRUG DEVELOPMENT AND APPROVAL PROCESS IN EU
FIG 60 MARKETING AUTHORIZATION PROCEDURES IN EU
FIG 61 CENTRALIZED PROCEDURE FOR DRUG APPROVAL
FIG 62 MUTUAL RECOGNITION PROCEDURE FOR DRUG APPROVAL
FIG 63 DECENTRALIZED PROCEDURE FOR DRUG APPROVAL
FIG 64 NEW DRUG DEVELOPMENT AND APPROVAL PROCESS IN JAPAN
FIG 65 EXPECTED LAUNCH TIME